Beyond first line treatment for advanced esophagogastric adenocarcinoma (EGAC): A phase 1 dose escalation study of regorafenib (Reg) combined with paclitaxel (PTX) (REPEAT study)

Category Primary study
JournalAnnals of Oncology
Year 2017
This article has no abstract
Epistemonikos ID: cd0d6f9cc851e431670f18d0ea4d0d1817bd2bc5
First added on: Feb 08, 2025